EUCTR2011-000265-12-LT进行中（未招募）不适用
A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic-Clonic Seizures
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Ages 12 years and older (in Germany, greater than or equal to 18 years of age [within the course of the study] at the time of the informed consent; in India, less than 65 years of age)
- •Clinical diagnosis of PGTC seizures in the setting of idiopathic
- •generalized epilepsy (with or without other subtypes of primary
- •generalized seizures) and experiencing = 3 PGTC seizures during the 8-week period prior to randomization
- •Have had a routine electroencephalogram (EEG) up to 5 years prior to or during the Baseline Period with electroencephalographic features consistent with primary generalized epilepsy (also called idiopathic generalized epilepsy); other concomitant anomaly should be explained by adequate past medical history. In the case of a normal historical EEG, EEG should be repeated. In the case of another normal EEG upon repeat, the presence or history of myoclonus or typical absence seizure, or first degree relative with PGTC seizures, is required. If the repeat EEG presents abnormalities compatible with PGTC seizures, no further action is required and the subject is eligible for enrollment.
- •On a fixed dose of one to a maximum of three concomitant AEDs for a minimum of 30 days prior to Baseline; only one inducer AED (i.e., carbamazepine, oxcarbazepine, or phenytoin) out of the maximum of three AEDs will be allowed
- •A vagal nerve stimulator (VNS) will be allowed, but it must have been implanted = 5 months prior to Baseline (stimulator parameters can not be changed for 30 days prior to Baseline and for the duration of the study)
- •Have had a computed tomography (CT) or magnetic resonance imaging (MRI) within the last 10 years (for adults) and 5 years (for adolescents) that ruled out a progressive cause of epilepsy
- •A ketogenic diet will be allowed as long as the subject has been on this diet for 5 weeks prior to randomization
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 33
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 115
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •Participated in a study involving administration of an investigational compound or device within the 30 days prior to Baseline, or within approximately 5 half-lives of the previous investigational compound, whichever is longer
- •Pregnant and/or nursing
- •Participated in previous perampanel studies
- •A history of status epilepticus that required hospitalization within 12 months prior to Baseline
- •Seizure clusters where individual seizures cannot be counted
- •A history of psychogenic seizures
- •Any suicidal ideation with intent with or without a plan at or within 6 months prior to Visit 2 (i.e., answering Yes” to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS)
- •Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the subject’s safety or study conduct
- •Concomitant diagnosis of Partial Onset Seizures (POS)
- •Progressive neurological disease
- •Clinical diagnosis of Lennox-Gastaut syndrome
- •History of drug or alcohol dependency or abuse within 2 years prior to Screening
- •Have had multiple drug allergies or a severe drug reaction to an AED(s), including dermatological (e.g., Stevens-Johnson syndrome), hematological, or organ toxicity reactions
- •If felbamate is used as a concomitant AED, subjects must be on felbamate for at least 2 years, with a stable dose for 60 days prior to Baseline. They must not have a history of white blood cell (WBC) count below = 2500/µL (2.50 1E+09/L), platelets < 100,000/µL, liver function tests (LFTs) > 3 times the upper limit of normal (ULN), or other indication of hepatic or bone marrow dysfunction while receiving felbamate.
- •Concomitant use of vigabatrin: Subjects who took vigabatrin in the past must be discontinued for approximately 5 months prior to Baseline, and must have documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in an automated visual perimetry test
- •Concomitant use of medications known to be inducers of CYP3A (with the exception of carbamazepine, oxcarbazepine, and phenytoin) including, but not limited to: rifampin, troglitazone, St John’s Wort, efavirenz, nevirapine, glucocorticoids (other than topical usage), modafinil, pioglitazone, and rifabutin within 30 days prior to Baseline. Concomitant use of barbiturates (except for seizure control indication) within 30 days prior to Baseline.
- •Use of intermittent rescue benzodiazepines (i.e., one to two doses over a 24-hour period considered one-time rescue) more than two times within the 30 days prior to Baseline
- •Subjects with active viral hepatitis (A, B, or C) as demonstrated by pre-existing positive serology
- •Evidence of significant active hepatic disease. Stable elevations of liver enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) due to concomitant medication(s) will be allowed if they are less than 3 times the upper limit of normal (ULN)
研究者
相似试验
进行中（未招募）
1 期
Study to assess the tolerability and efficacy of AMG 145 in patients withheterozygous familial hypercholesterolemiaHeterozygous Familial HypercholesterolemiaMedDRA version: 14.1Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 100000004850EUCTR2012-001365-32-NLAmgen Inc331
进行中（未招募）
1 期
Study to determine the adequate dose of a new medicine omecantiv mecarbil compared to placebo in patients with a heart condition whereby the ability of the heart to pump enough blood to meet the body’s need at all times is reduced.Chronic Heart Failure and Left Ventricular Systolic DysfunctionMedDRA version: 17.0Level: PTClassification code 10063083Term: Chronic left ventricular failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2012-000327-40-BEAmgen Inc.570
进行中（未招募）
1 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeMedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersDyslipidemiaEUCTR2018-004565-14-PLAmgen Inc.12,000
进行中（未招募）
1 期
A Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when Evolocumab (AMG 145) is used in combination With Statin Therapy In Patients with Clinically Evident Cardiovascular DiseaseDyslipidemiaMedDRA version: 19.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2012-001398-97-LTAmgen Inc27,500
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart FailureAcute heart failureMedDRA version: 14.1Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2010-021003-24-LTAmgen Inc600